Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM)

Rassaf T, Totzeck M, Backs J, Bokemeyer C, Hallek M, Hilfiker-Kleiner D, et al. Onco-cardiology: consensus paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol. 2020;109(10):1197–222.

PubMed  PubMed Central  Google Scholar 

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801.

PubMed  Google Scholar 

Michel L, Schadendorf D, Rassaf T. Oncocardiology: new challenges, new opportunities. Herz. 2020;45(7):619–25.

PubMed  PubMed Central  Google Scholar 

Totzeck M, Lutgens E, Neilan TG. Are we underestimating the potential for cardiotoxicity related to immune checkpoint inhibitors? Eur Heart J. 2021;42(16):1632–5.

PubMed  Google Scholar 

Totzeck M, Michel L, Lin Y, Herrmann J, Rassaf T. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur Heart J. 2022;43(20):1928–40.

PubMed  PubMed Central  Google Scholar 

Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;01(280):163–75.

Google Scholar 

Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis. 2018;10(Suppl 35):S4282–95.

PubMed  PubMed Central  Google Scholar 

Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients. J Am Heart Assoc. 2017;6(8):e006278.

PubMed  PubMed Central  Google Scholar 

Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447–58.

CAS  PubMed  Google Scholar 

Michel L, Totzeck M, Lehmann L, Finke D. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. Herz. 2020;45(7):645–51.

PubMed  Google Scholar 

D’Souza M, Nielsen D, Svane IM, Iversen K, Rasmussen PV, Madelaire C, et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. 2021;42(16):1621–31.

PubMed  Google Scholar 

Mrotzek SM, Rassaf T, Totzeck M. Cardiovascular damage associated with chest irradiation. Front Cardiovasc Med. 2020;7:41.

CAS  PubMed  PubMed Central  Google Scholar 

Haddy N, Diallo S, El-Fayech C, Schwartz B, Pein F, Hawkins M, et al. Cardiac diseases following childhood cancer treatment: cohort study. Circulation. 2016;133(1):31–8.

CAS  PubMed  Google Scholar 

Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–60.

PubMed  Google Scholar 

Löffler AI, Salerno M. Cardiac MRI for the evaluation of oncologic cardiotoxicity. J Nucl Cardiol. 2018;25(6):2148–58.

PubMed  PubMed Central  Google Scholar 

Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280–99.

PubMed  Google Scholar 

Keramida K, Farmakis D. Right ventricular involvement in cancer therapy-related cardiotoxicity: the emerging role of strain echocardiography. Heart Fail Rev. 2021;26(5):1189–93.

CAS  PubMed  Google Scholar 

Rui Zhao, Fang Shu, Chujie Zhang, Song Feiyan Xu, Yuchen Guo Ye, et al. Early detection and prediction of anthracycline-induced right ventricular cardiotoxicity by 3-dimensional echocardiography. JACC CardioOncol. 2020;2(1):13–22.

Google Scholar 

Ribeiro ML, Jorge AJL, Nacif MS, de Martins WA. Early detection and monitoring of cancer chemotherapy-related left ventricular dysfunction by imaging methods. Arq Bras Cardiol. 2019;112(3):309–16.

CAS  PubMed  PubMed Central  Google Scholar 

Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii155-166.

PubMed  Google Scholar 

Alvarez JA, Russell RR. Cardio-oncology: the nuclear option. Curr Cardiol Rep. 2017;19(4):31.

PubMed  Google Scholar 

Kim H, Chung WB, Cho KI, Kim BJ, Seo JS, Park SM, et al. Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice: an opinion paper from the working group on cardio-oncology of the Korean Society of Echocardiography. J Cardiovasc Ultrasound. 2018;26(1):1–25.

PubMed  PubMed Central  Google Scholar 

Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70(20):2536–51.

PubMed  PubMed Central  Google Scholar 

Farrell MB, Galt JR, Georgoulias P, Malhotra S, Pagnanelli R, Rischpler C, et al. SNMMI procedure standard/EANM guideline for gated equilibrium radionuclide angiography. J Nucl Med Technol. 2020;48(2):126–35.

PubMed  Google Scholar 

Tissot H, Roch V, Morel O, Veran N, Perrin M, Claudin M, et al. Left ventricular ejection fraction determined with the simulation of a very low-dose CZT-SPECT protocol and an additional count-calibration on planar radionuclide angiographic data. J Nucl Cardiol. 2019;26(5):1539–49.

PubMed  Google Scholar 

Sachpekidis C, Sachpekidis V, Kopp-Schneider A, Arsos G, Moralidis E. Equilibrium radionuclide angiography: intra- and inter-observer repeatability and reproducibility in the assessment of cardiac systolic and diastolic function. J Nucl Cardiol. 2021;28(4):1304–14.

PubMed  Google Scholar 

Russell RR, Alexander J, Jain D, Poornima IG, Srivastava AV, Storozynsky E, et al. The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. J Nucl Cardiol. 2016;23(4):856–84.

PubMed  Google Scholar 

Kahanda MG, Hanson CA, Patterson B, Bourque JM. Nuclear cardio-oncology: from its foundation to its future. J Nucl Cardiol. 2020;27(2):511–8.

PubMed  Google Scholar 

Verberne HJ, Acampa W, Anagnostopoulos C, Ballinger J, Bengel F, De Bondt P, et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision. Eur J Nucl Med Mol Imaging. 2015;42(12):1929–40.

CAS  PubMed  PubMed Central  Google Scholar 

Pryma DA, Ravizzini G, Amar D, Richards VL, Patel JB, Strauss HW. Cardiovascular risk assessment in cancer patients undergoing major surgery. J Nucl Cardiol. 2005;12(2):151–7.

PubMed  Google Scholar 

Chang K, Sarkiss M, Won KS, Swafford J, Broemeling L, Gayed I. Preoperative risk stratification using gated myocardial perfusion studies in patients with cancer. J Nucl Med. 2007;48(3):344–8.

PubMed  Google Scholar 

Chandra S, Lenihan DJ, Wei W, Yusuf SW, Tong AT. Myocardial perfusion imaging and cardiovascular outcomes in a cancer population. Tex Heart Inst J. 2009;36(3):205–13.

PubMed  PubMed Central  Google Scholar 

Prosnitz RG, Hubbs JL, Evans ES, Zhou SM, Yu X, Blazing MA, et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer. 2007;110(8):1840–50.

PubMed  Google Scholar 

Sioka C, Exarchopoulos T, Tasiou I, Tzima E, Fotou N, Capizzello A, et al. Myocardial perfusion imaging with (99 m)Tc-tetrofosmin SPECT in breast cancer patients that received postoperative radiotherapy: a case-control study. Radiat Oncol. 2011;8(6):151.

Google Scholar 

Imbert L, Poussier S, Franken PR, Songy B, Verger A, Morel O, et al. Compared performance of high-sensitivity cameras dedicated to myocardial perfusion SPECT: a comprehensive analysis of phantom and human images. J Nucl Med. 2012;53(12):1897–903.

PubMed  Google Scholar 

Sciagrà R, Lubberink M, Hyafil F, Saraste A, Slart RHJA, Agostini D, et al. EANM procedural guidelines for PET/CT quantitative myocardial perfusion imaging. Eur J Nucl Med Mol Imaging. 2021;48(4):1040–69.

PubMed  Google Scholar 

Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient. JACC Cardiovasc Imaging. 2018;11(8):1173–86.

PubMed  Google Scholar 

Rasmussen T, Kjær A, Lassen ML, Pedersen AN, Specht L, Aznar MC, et al. No changes in myocardial perfusion following radiation therapy of left-sided breast cancer: a positron emission tomography study. J Nucl Cardiol. 2021;28(5):1923–32.

PubMed  Google Scholar 

Żyromska A, Małkowski B, Wiśniewski T, Majewska K, Reszke J, Makarewicz R. 15O–H2O PET/CT as a tool for the quantitative assessment of early post-radiotherapy changes of heart perfusion in breast carcinoma patients. Br J Radiol. 2018;91(1088):20170653.

PubMed  PubMed Central  Google Scholar 

Laursen AH, Elming MB, Ripa RS, Hasbak P, Kjær A, Køber L, et al. Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. J Nucl Cardiol. 2020;27(5):1698–707.

PubMed  Google Scholar 

Biersmith MA, Tong MS, Guha A, Simonetti OP, Addison D. Multimodality cardiac imaging in the era of emerging cancer therapies. J Am Heart Assoc. 2020;9(2):e013755.

CAS  PubMed  PubMed Central  Google Scholar 

Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J. 1981;102(4):709–18.

CAS  PubMed  Google Scholar 

Druck MN, Gulenchyn KY, Evans WK, Gotlieb A, Srigley JR, Bar-Shlomo BZ, et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer. 1984;53(8):1667–74.

CAS  PubMed  Google Scholar 

Ewer MS, Ali MK, Mackay B, Wallace S, Valdivieso M, Legha SS, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol. 1984;2(2):112–7.

CAS  PubMed  Google Scholar 

Mercurio V, Cuomo A, Della Pepa R, Ciervo D, Cella L, Pirozzi F, et al. What is the cardiac impact of chemotherapy and subsequent radiotherapy in lymphoma patients? Antioxid Redox Signal. 2019;31(15):1166–74.

留言 (0)

沒有登入
gif